Rashmi Kapur, MD
Ophthalmology · Elgin, ILNPI 1962679498
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), travel and lodging and gifts — rather than concentrated in one kind of arrangement. US Oncology Corporate, Inc. accounts for 60.6% of it on its own, with 4 other manufacturers making up the rest.
Across 14 payments — averaging $184.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Oncology Corporate, Inc.$2K
- Onmark, Inc.$942
- ANI Pharmaceuticals, Inc.$30
- Biogen$24
- Carl Zeiss Meditec AG$19
What the payments were for
- Travel & lodging$1,14044%
- Food & beverage$1,42255%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Oncology Corporate, Inc. | 3 | $1,566 |
| Onmark, Inc. | 8 | $942 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Biogen | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$2,582 in reported general payments places this provider in the 65th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 111 | $4,165 |
| MyrbetriqMirabegron | 13 | $3,061 |
| Ketorolac Tromethamine | 107 | $2,459 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $684 |
| Atropine Sulfate | 26 | $605 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $347 |
| ErythromycinErythromycin Base | 30 | $284 |
| Proparacaine Hcl | 13 | $225 |
| Brimonidine Tartrate | 27 | $155 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Elgin
- Rehan HussainElgin$32K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.